Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of HIP2503 and HCP1306 in Healthy Subjects
NCT07297693Phase 1Not yet recruiting
- Sponsor
- Hanmi Pharmaceutical
- Start
- Dec 2025
- Primary completion
- Mar 2026
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial in migraine (2 arms), sponsored by Hanmi Pharmaceutical. Primary endpoints: Area Under the Curve to time t and Maximum Plasma Concentration. Planned start Dec 2025; status: not yet recruiting.
02
Conditions
migraine
Beyond the preview
Go deeper on NCT07297693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07297693.